XML 33 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Revenues (Tables)
 9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenues
The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions):
Three Months Ended September 30, 2020Three Months Ended September 30, 2019
U.S.EuropeOther LocationsTotalU.S.EuropeOther LocationsTotal
Product sales:
Atripla$99 $5 $9 $113 $132 $10 $7 $149 
Biktarvy1,584 194 113 1,891 1,106 108 45 1,259 
Complera/Eviplera26 35 9 70 40 45 8 93 
Descovy424 49 35 508 256 63 44 363 
Genvoya669 116 61 846 761 152 65 978 
Odefsey309 116 12 437 317 111 8 436 
Stribild27 13 2 42 63 18 13 94 
Truvada492 6 11 509 688 14 19 721 
Other HIV(1)
10 1 2 13 3 1 1 5 
Revenue share – Symtuza(2)
82 34 2 118 68 36 — 104 
AmBisome18 58 35 111 9 57 33 99 
Ledipasvir/Sofosbuvir(3)
36 11 37 84 54 14 56 124 
Letairis78 — — 78 121 — — 121 
Ranexa— — — — 31 — — 31 
Sofosbuvir/Velpatasvir(4)
170 74 86 330 282 118 116 516 
Veklury785 60 28 873 — — — — 
Vemlidy99 8 70 177 78 6 50 134 
Viread3 8 21 32 7 15 35 57 
Vosevi33 9 3 45 42 12 9 63 
Yescarta85 51 2 138 86 32 — 118 
Zydelig8 9 — 17 13 13 — 26 
Other(5)
39 20 2 61 42 (21)4 25 
Total product sales5,076 877 540 6,493 4,199 804 513 5,516 
Royalty, contract and other revenues24 60 — 84 20 67 1 88 
Total revenues$5,100 $937 $540 $6,577 $4,219 $871 $514 $5,604 
Nine Months Ended September 30, 2020Nine Months Ended September 30, 2019
U.S.EuropeOther LocationsTotalU.S.EuropeOther LocationsTotal
Product sales:
Atripla$275 $17 $19 $311 $387 $52 $33 $472 
Biktarvy4,346 528 314 5,188 2,868 229 71 3,168 
Complera/Eviplera77 124 17 218 126 179 26 331 
Descovy1,124 156 103 1,383 735 200 128 1,063 
Genvoya1,927 376 183 2,486 2,222 522 229 2,973 
Odefsey851 341 36 1,228 865 328 27 1,220 
Stribild100 42 12 154 208 60 30 298 
Truvada1,245 20 37 1,302 1,896 88 61 2,045 
Other HIV(1)
24 4 21 49 23 3 11 37 
Revenue share – Symtuza(2)
244 112 6 362 165 89 — 254 
AmBisome46 166 113 325 27 174 96 297 
Ledipasvir/Sofosbuvir(3)
113 26 124 263 257 63 222 542 
Letairis241 — — 241 522 — — 522 
Ranexa9 — — 9 205 — — 205 
Sofosbuvir/Velpatasvir(4)
646 253 330 1,229 731 428 341 1,500 
Veklury785 60 28 873 — — — — 
Vemlidy248 22 194 464 214 15 122 351 
Viread10 27 100 137 28 57 119 204 
Vosevi93 26 13 132 140 43 18 201 
Yescarta283 144 7 434 275 59 — 334 
Zydelig24 30 1 55 36 42 1 79 
Other(5)
124 54 6 184 119 96 12 227 
Total product sales12,835 2,528 1,664 17,027 12,049 2,727 1,547 16,323 
Royalty, contract and other revenues55 170 16 241 61 181 5 247 
Total revenues$12,890 $2,698 $1,680 $17,268 $12,110 $2,908 $1,552 $16,570 
________________________________
(1)Includes Emtriva and Tybost.
(2)Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC.
(3)Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.
(4)Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.
(5)
Includes Cayston, Hepsera, Sovaldi and Tecartus. Europe product sales included unfavorable adjustments recorded in 2019 for statutory rebates related to sales of Sovaldi made in prior years.
Revenues from Major Customers
The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):
Three Months EndedNine Months Ended
 September 30,September 30,
 2020201920202019
AmerisourceBergen Corporation30 %21 %25 %21 %
Cardinal Health, Inc.19 %21 %22 %21 %
McKesson Corporation22 %23 %22 %21 %